Abstract
The idea that a commonplace, nontoxic vitamin can often ameliorate so profound, baffling, and severely disabling a condition as autism is incredible to many people. Yet despite its initial implausibility, the evidence is clear and compelling: Vitamin B6, when given in large amounts, especially when given with moderate amounts of magnesium and the other B vitamins, can safely bring about substantial improvement in a significant proportion of children and adults diagnosed as autistic. The improvement is seen not only in behavior but also in laboratory measurements of brain waves and urinary constituents. In this chapter I will review the available evidence bearing on the use of megadose vitamin B6 in the treatment of autistic children and adults.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Barthelemy, C., Garreau, B., Leddet, I., Ernouf, D., Muh, J. P., & Lelord, G. (1981). Behavioral and biological effects of oral magnesium, vitamin B6, a combined magnesium — B6 administration in autistic children. Magnesium Bulletin, 3, 150–153.
Barthelemy, C., Garreau, B., Leddet, I., Sauvage, D., Muh, J. P., Lelord, G., & Callaway, E. (1983). Intérèt des echelles de comportement et des dosages de l’acide homovanillique urinaire pour le contrôle des effets d’un traitement associant vitamine B6 et magnesium chez des enfants ayant un comportement autistique. Neuropsychiatrie de l’Enfance, 31, 289–301.
Berger, A., & Schaumburg, H. H. (1984). More on neuropathy from pyridoxine abuse. New England Journal of Medicine, 311, 986–987.
Bonisch, V. E. (1968). Erfahrungen met pyrithioxin bei hirngeschadigten kindern mit autistischem syndrom. Praxis der Kinderpsychologie, 8, 308–310.
Coleman, M., & Gillberg, C. (1985). The biology of the autistic syndromes. New York: Praeger.
Coleman, M., Sobel, S., Bhagavan, H., Coursin, D., Marquardt, M., Guay, M., & Hunt, C. (1985). A double-blind study of vitamin B6 in Down’s syndrome infants. Part 1—Clinical and biochemical results. Journal of Mental Deficiency Research, 29, 233–240.
Coleman, M., Steinberg, G., Tippett, J., Bhagavan, H. N., Coursin, D. B., Gross, M., Lewis, C., & De Veau, L. (1979). A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate. Biological Psychiatry, 141, 741–751.
Davis, A. (1959). Let’s have healthy children. New York: Harcourt Brace Jovanovich.
Davis, A. (1965). Let’s get well. New York: Harcourt, Brace, and World.
Davis, D. (1978). Using vitamin A safely. Osteopathic Medicine, 3, 31–43.
DeVeaugh-Geiss, J., & Manion, L. (1978). High-dose pyridoxine in tardive dyskinesia. Journal of Clinical Psychiatry, 39, 573–575.
Ellman, G. (1981, November). Pyridoxine effectiveness on autistic patients at Sonoma State Hospital. Paper presented at the Research Conference on Autism, San Diego.
Gamier, C., Comoy, E., Barthelemy, C., Leddet, I., Garreau, B., Muh, J. P., & Lelord, G. (1986). Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children. Journal of Autism and Developmental Disorders, 16, 23–29.
Gualtieri, C. T., Quade, D., Hicks, R. E., Mayo, J. P., & Schroeder, S. R. (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. American Journal of Psychiatry, 141, 20–23.
Gualtieri, C. T., van Bourgondien, M. E., Hartz, C., Schopler, E., & Marcus, L. (1981, May). A pilot study of pyridoxine treatment in autistic children. Paper presented at the American Psychiatric Association meeting, New Orleans.
Hawkins, D. R. (1986). The prevention of tardive dyskinesia with high dosage vitamins: A study of 58,000 patients. Journal of Orthomolecular Medicine, 1, 24–26.
Heeley, A. F., & Roberts, G. E. (1966). A study of tryptophan metabolism in psychotic children. Developmental Medicine and Child Neurology, 3, 708–718.
Jonas, C., Etienne, T., Barthelemy, C., Jouve, J., & Mariotte, N. (1984). Intérèt clinique et biochimique de l’association vitamine B6 + magnesium dans le traitement de l’autisme résiduel è l’âge adults. Therapie, 39, 661–669.
Lelord, G., Muh, J. P., Barthelemy, C., Martineau, J., Garreau, B., & Callaway, E. (1981). Effects of pyridoxine and magnesium on autistic symptoms—Initial observations. Journal of Autism and Developmental Disorders, 11, 219–230.
Martineau, J., Barthelemy, C., Garreau, B., & Lelord, G. (1985). Vitamin B6, magnesium and combined B6-Mg: Therapeutic effects in childhood autism. Biological Psychiatry, 20, 467–468.
Martineau, J., Barthelemy, C., & Lelord, G. (1986). Long-term effects of combined vitamin Bomagnesium administration in an autistic child. Biological Psychiatry, 21, 511–518.
Martineau, J., Garreau, B., Barthelemy, C., & Lelord, G. (1982). Comparative effects of oral B6, B6-Mg, and Mg administration on evoked potentials conditioning in autistic children. In A. Rothenberger (Ed.) Proceedings: Symposium and event-related potentials in children, Essen, F.R.G. June 11–13, 1982, (pp. 411–416). Amsterdam: Elsevier Biomedical Press.
Ornitz, E. (1985). Should autistic children be treated with haloperidol? American Journal of Psychiatry, 142, 883.
Perry, R., Campbell, M., Green, W. H., Small, A. M., Die Trill, M. L., Meiselas, K., Golden, R., & Deutsch, S. I. (1985). Neuroleptic-related dyskinesias in autistic children: A prospective study. Psychopharmacology Bulletin, 21, 140–143.
Rimland, B. (1973). High dosage levels of certain vitamins in the treatment of children with severe mental disorders. In D. R. Hawkins & L. Pauling (Eds.), Orthomolecular psychiatry (pp. 513–539). New York: W. H. Freeman.
Rimland, B. (1974). An orthomolecular study of psychotic children. Orthomolecular Psychiatry, 3, 371–377.
Rimland, B., Callaway, E., & Dreyfus, P. (1978). The effects of high doses of vitamin B6 on autistic children: A double-blind crossover study. American Journal of Psychiatry, 135, 472–475.
Rosenberg, L. (1970). Vitamin-dependent genetic disease. Hospital Practice, July, 59–66.
Schaumburg, H., Kaplan, J., Windebank, A., Vick, N., Rasmus, S., Pleasure, D., & Brown, M. J. (1983). Sensory neuropathy from pyridoxine abuse. New England Journal of Medicine, 309, 445–448.
Sievers, M. L., & Herrier, R. N. (1984). Sensory neuropathy from pyrodoxine abuse. New England Journal of Medicine, 310, 198.
Silverman, M., & Lee, P. R. (1974). Pills, profits and politics. Berkeley: University of California Press.
Tkacz, C., & Hawkins, D. R. (1981). A preventive measure for tardive dyskinesia. Orthomolecular Psychiatry, 10, 119–123.
Wilcken, B., & Turner, B. (1973). Homocystinuria: Reduced folate levels during pyridoxine treatment. Archives of Diseases of Children, 48, 58–62.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rimland, B. (1987). Megavitamin B6 and Magnesium in the Treatment of Autistic Children and Adults. In: Schopler, E., Mesibov, G.B. (eds) Neurobiological Issues in Autism. Current Issues in Autism. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1992-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1992-2_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1994-6
Online ISBN: 978-1-4899-1992-2
eBook Packages: Springer Book Archive